Clinical trials are notoriously expensive, time consuming, and risky. Failure comes at a very high cost (millions of dollars and months of development time wasted), yet studies show that the rate of ...

Despite being a cornerstone of cancer treatment advancement, clinical trials remain inaccessible for many patients because of structural, socioeconomic, and systemic barriers. In this ...

By fine-tuning domain-specific models with real clinical operations data — such as historical performance, feasibility ...

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and ...

Furthermore, increasing complexity in cancer clinical trial design has led to challenges such as protocol deviations, slow enrollment leading to lengthened durations of trial, and escalating costs. By ...

Clinical trial design decisions impact costs, access, and evidence gaps, with breast cancer as the most studied disease globally. The US leads in trial activity, with China showing rapid growth, ...

Expanding clinical trial access locally reduces logistical and financial barriers, making participation feasible for underserved populations. Addressing myths about clinical trials helps patients ...

The number of clinical trials conducted in China is rising dramatically. Historically, scientists have had concerns about the quality of research in China. Researchers within China have pushed to ...